After advancing in lockstep through the pandemic, the fortunes of the biotechs have diverged as their use of COVID-19 windfalls has taken shape.
Moderna (NasdaqGS:MRNA) is shifting away from self-funding new Phase III vaccine trials in response to increased vaccine hesitancy in the U.S. The company is seeking external partners to finance and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results